Small · 2024 · 34 citations · 44 references
Life SciencesNeurosciencePharmacologyDrug DeliveryMolecular NeuroscienceNeurodegenerationAlzheimer DiseaseAmyloid FormationLiposomal FormulationsLiposome-based DeliveryNeurodegenerative DiseasesNeurodegenerative DisordersAmyloid Beta AggregationAmyloid FibrilsEarly DiagnosisLiposome Delivery SystemsLiposomesTargeted LiposomesTherapeutic Targeting Of AmyloidTransgenic Mice
Early detection and treatment are crucial for Alzheimer's disease (AD) management. Current diagnostic and therapeutic methods focus on late-stage amyloid fibrils and plaques, overlooking toxic soluble amyloid β oligomers (AβOs) accumulating early in AD. A multifunctional liposome-based platform is designed for early diagnosis and therapy of AD, leveraging a novel self-assembled cyclic d,l-α-peptide (CP-2) that selectively targets AβOs. Biocompatible CP-2 conjugated liposomes (CP-2-LPs) effectively disrupt Aβ aggregation and mitigate Aβ-mediated toxicity in human neuroblastoma cells. In transgenic Caenorhabditis elegans AD models, CP-2-LPs significantly outperformed free CP-2 by improving cognitive and behavioral functions, extending lifespan, and reducing toxic AβO levels. Intravenous injection of fluorescently labeled CP-2-LPs reveals effective blood-brain barrier penetration, with significantly higher brain fluorescence in transgenic mice than WT, enabling precise diagnosis. These findings underscore CP-2-LPs as a valuable tool for early detection and targeted therapy in AD.
44
Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis
Rakez Kayed, Elizabeth Head, Jennifer L. Thompson et al. · Science · 2003 · 4.1K citations
Holly D. Oakley, Sarah L. Cole, Sreemathi Logan et al. · Journal of Neuroscience · 2006 · 3.6K citations · Full text
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Sylvain Lesné, Ming Teng Koh, Linda Kotilinek et al. · Nature · 2006 · 2.8K citations